Business Description
Scancell Holdings PLC
ISIN : GB00B63D3314
Total Employee Number:
61Description
Scancell Holdings PLC is a clinical-stage biotechnology company developing targeted off-the-shelf active immunotherapies to generate safe and long-lasting tumour-specific immunity for a cancer-free future. iSCIB1+, a product from its DNA ImmunoBody platform (AvidiMab), has demonstrated safe, durable, and clinically meaningful benefit as a monotherapy as well as additional benefit when combined with checkpoint therapies in an ongoing Phase 2 trial in melanoma. Modi-1, the peptide immunotherapy from its Moditope platform, is being investigated in a Phase 2 study in a broad range of solid tumours. In addition, the company has established a subsidiary with the intention to hold and develop an early-stage pipeline of high-affinity GlyMab antibodies targeting tumour-specific glycans.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.53 | |||||
Equity-to-Asset | -0.54 | |||||
Debt-to-Equity | -1.93 | |||||
Debt-to-EBITDA | -2.89 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -4.84 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -37.5 | |||||
3-Year FCF Growth Rate | 17 |
Momentum Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 45.78 | |||||
9-Day RSI | 47.49 | |||||
14-Day RSI | 47.49 | |||||
3-1 Month Momentum % | -62.38 | |||||
6-1 Month Momentum % | -56.07 | |||||
12-1 Month Momentum % | 18.75 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 0.56 | |||||
Quick Ratio | 0.56 | |||||
Cash Ratio | 0.36 | |||||
Days Sales Outstanding | 44.2 | |||||
Days Payable | 4240.95 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.3 | |||||
Shareholder Yield % | -7.15 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 94.95 | |||||
Operating Margin % | -283.34 | |||||
Net Margin % | -116.98 | |||||
EBITDA Margin % | -118.79 | |||||
FCF Margin % | -211.02 | |||||
OCF Margin % | -180.6 | |||||
ROA % | -30.02 | |||||
ROIC % | -32.91 | |||||
3-Year ROIIC % | -11.13 | |||||
ROC (Joel Greenblatt) % | -738.76 | |||||
ROCE % | -201.65 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 20.3 | |||||
EV-to-EBIT | -22.8 | |||||
EV-to-EBITDA | -25.97 | |||||
EV-to-Forward-EBITDA | -18.18 | |||||
EV-to-Revenue | 30.85 | |||||
EV-to-Forward-Revenue | 60.55 | |||||
EV-to-FCF | -14.41 | |||||
Earnings Yield (Greenblatt) % | -4.39 | |||||
FCF Yield % | -7.32 |
GF Valueâ„¢
Scancell Holdings PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Scancell Holdings PLC Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2027 | 2027-01-29 14:00 | In 138 days | ||
| Second quarter earnings results for 2027 | 2027-01-29 | In 137 days | ||
| General meeting for 2026 | 2026-10-30 15:00 | In 47 days | ||
| H.C. Wainwright 28(th) Annual Global Investment Conference | 2026-09-16 11:30 | In 3 days | ||
| Fourth quarter earnings conference call for 2026 | 2026-09-11 12:00 | 0.14 (+68.29%) | ||
| Annual report for 2026 | 2026-09-11 | 0.14 (+68.29%) | ||
| Fourth quarter earnings results for 2026 | 2026-09-11 | 0.14 (+68.29%) | ||
| Second quarter earnings conference call for 2026 | 2026-01-29 14:00 | 0.11 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-01-29 | 0.11 (+0.00%) | ||
| General meeting for 2025 | 2025-10-30 15:00 | 0.08 (+0.00%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers